RxDoctor Payments Data

Stacy Frankel, MD

Dermatology · Tamarac, FLNPI 1982638961

Payments from drug & device makers

$211,717in general payments, 2019–2025

Across 154 payments — averaging $1374.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$162K
  • Pfizer$29K
  • AbbVie$19K
  • Johnson & Johnson$412
  • Regeneron Healthcare Solutions, Inc.$272
  • Myriad Genetic Laboratories, Inc.$220
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$3,07996%
  • Education$1164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,717 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$192,604
Medicare patients
458
Services billed
2,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$245,618
OtezlaApremilast13$63,966
OpzeluraRuxolitinib Phosphate30$59,421
Ketoconazole555$10,057
Fluorouracil100$7,225
Betamethasone Dipropionate165$6,760
Pimecrolimus25$6,479
Tacrolimus37$6,220
Triamcinolone Acetonide299$3,780
Tretinoin36$3,260
Clobetasol Propionate97$2,876
Clindamycin Phosphate79$2,740
Ciclopirox79$1,786
Mupirocin198$1,389
Metronidazole40$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$154$63,96613 claims
Incyte CorporationOpzelura$217$59,42130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →